Acuta Capital Partners’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-495,772
| Closed | -$26.1M | – | 28 |
|
|
2026
Q1 | $26.1M | Sell |
495,772
-141,323
| -22% | -$5.8M | 18.44% | 2 |
|
|
2025
Q4 | $25.7M | Buy |
637,095
+134,298
| +27% | +$3.1M | 17.48% | 1 |
|
|
2025
Q3 | $3.78M | Buy |
502,797
+38,933
| +8% | +$249K | 3.9% | 9 |
|
|
2025
Q2 | $1.73M | Buy |
463,864
+138,314
| +42% | +$432K | 2.42% | 15 |
|
|
2025
Q1 | $899K | Sell |
325,550
-121,950
| -27% | -$498K | 1.04% | 25 |
|
|
2024
Q4 | $2.48M | Sell |
447,500
-39,500
| -8% | -$267K | 2.49% | 15 |
|
|
2024
Q3 | $4.06M | Buy |
487,000
+117,720
| +32% | +$969K | 3.29% | 11 |
|
|
2024
Q2 | $2.51M | Sell |
369,280
-95,799
| -21% | -$580K | 2.12% | 19 |
|
|
2024
Q1 | $3.05M | Sell |
465,079
-90,181
| -16% | -$589K | 1.98% | 19 |
|
|
2023
Q4 | $3.6M | Hold |
555,260
| – | – | 2.03% | 21 |
|
|
2023
Q3 | $2.79M | Sell |
555,260
-414,740
| -43% | -$2.63M | 1.87% | 20 |
|
|
2023
Q2 | $8.49M | Sell |
970,000
-129,309
| -12% | -$1.51M | 5.75% | 3 |
|
|
2023
Q1 | $13M | Sell |
1,099,309
-691
| -0.1% | -$6.6K | 9.59% | 3 |
|
|
2022
Q4 | $11.2M | Buy |
1,100,000
+749,298
| +214% | +$4.99M | 6.89% | 4 |
|
|
2022
Q3 | $2.07M | Buy |
+350,702
| New | +$1.3M | 0.89% | 26 |
|
Other funds holding TERN
Acuta Capital Partners's TERN Position: Q2 2026 in Review
Acuta Capital Partners sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 495,772 shares — an estimated $26.1M sold.
Acuta Capital Partners first reported a position in TERN in Q3 2022 and held it in 15 quarters. The position peaked at $26.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Acuta Capital Partners reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Acuta Capital Partners sold 495,772 Terns Pharmaceuticals shares in Q2 2026, an estimated $26.1M.
- Acuta Capital Partners first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 15 quarters.
- Acuta Capital Partners's Terns Pharmaceuticals position peaked at $26.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.